# Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

> **NCT00920309** · PHASE2,PHASE3 · TERMINATED · sponsor: **Yale University** · enrollment: 21 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease

## Interventions

- **DRUG:** Rapamycin
- **OTHER:** Standard of Care-Placebo

## Key facts

- **NCT ID:** NCT00920309
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD
- **Last updated:** 2014-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920309, "Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00920309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*